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After rotating through hospitals around 
London as a physician, Danny Douek 
gravitated toward a research labora-
tory at Hammersmith Hospital, where 
he earned his PhD by tackling the 
thymus. He continued to monitor the 
thymus as a postdoc at the University 
of Texas Southwestern Medical Center 
in Dallas, finding that antiretroviral 
therapy helps to increase thymic out-
put in HIV-infected 
patients (1). Now a se-
nior investigator at the 
National Institutes of 
Health (NIH) in 
Bethesda, Douek peers 
into the gastrointestinal 
tract of HIV-infected 
patients. The virus 
strikes the gut hard and 
fast to deplete CD4  +   T 
cells and breach one of the body’s 
most important immunological barri-
ers (2). More recently, Douek has 
been trying to halt HIV progression 
by taking advantage of “public” T cell 
responses, in which T cells from dif-
ferent individuals bear identical T cell 
receptors (3, 4).
STETHOSCOPES IN THE GARAGE
When did HIV fi  rst creep onto your radar?
I fi  rst learned about HIV around 1984 
when I was in medical school at Oxford. 
And then as a young doctor I was look-
ing after people with HIV infections. 
Usually when we saw them, they were 
in the hospital dying of AIDS. It was 
really quite tragic before the days of 
wonderful therapies like HAART.
Did this drive you to study HIV as a 
research scientist?
No, I had always wanted to be a scientist. 
But my clinical training did instill the 
sensibility that I want to make ill people 
better. And so after I did a PhD in immu-
nology, I wanted to do something that 
translated more into the clinical arena. 
My PhD mentor suggested HIV.
Do you ever consider switching fi  elds?
Yes, I fi  nd neuroscience absolutely fas-
cinating. I fi   nd the science of aging 
fascinating. I fi  nd plants fascinating.
Do you honestly fi  nd plants fascinating?
Yes, I want to know about their genes, 
what makes them grow, why they’re 
plants… I don’t think there’s anything in 
science that I don’t fi  nd interesting. I like 
organic chemistry. I love quantum 
physics. However, I do fi  nd  relativity 
diffi   cult to understand.
Is it true that you have an interest in 
old cars too?
I used to drive a 1966 Chevy Bel Air, but 
that wasn’t big enough so I got a lime 
green 1972 Buick Electra. It’s the longest 
Buick ever built. It seats four in the front 
and probably fi  ve in the backseat.
When things go wrong with the 
car, I bring people—usually from the 
laboratory—around the house to have 
a few beers and fix things. It’s fun because 
there’s a whole diagnostic procedure in 
trying to work out what’s wrong with 
the car. Actually, the only time I use 
my stethoscope these days is to listen to 
vacuum leaks.
FAITH AND VACCINES
Do you have a scientifi  c hero?
There’s a bunch of them. I think Sir 
Peter Medawar is one of the real greats, 
certainly in immunology. He had in-
credibly original ideas. My rabbi re-
cently asked if scientists come up with 
completely original ideas. And I said, 
“To be honest, there are very few of 
those.” But I think Medawar came up 
with some really original things. One 
of them being the genetic control of 
the immune response.
Does your rabbi often inspire you to refl  ect 
on science?
Sure. I’m a devout atheist but some-
what observant. I love going to syna-
gogue. I relax, recharge my batteries… 
a lot of people who go to my syna-
gogue also work at the NIH. Some of 
my best ideas for experiments have 
come from chatting after services with 
other scientists.
How is it possible to be an observant 
atheist?
I recently heard that Jews are skewed 
toward atheism compared with other 
religions. I think it’s because it’s a hyper-
rational religion. Some of my orthodox 
friends might disagree with me, but I 
don’t think you need a belief in God to 
be Jewish. I think as a Jew you can go to 
synagogue, you can pray, you can do 
good things and, well, my rabbi under-
stands me completely.
In fact, last Yom Kippur I gave a 
sermon on a rational argument for 
prayer to God for those who don’t be-
lieve in God. If you go back to the 
Talmud,  the rabbis wrote that there 
would be no more miracles, that God 
no longer played a role in the affairs of 
man. And so you don’t need to believe 
in magic or miracles or anything like 
that in Judaism.
If a scientist is defined as a person who acquires knowledge methodologically, 
Douek fits the bill in every way.
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Do you have faith in a future HIV vaccine?
I’ve become more, not less, optimistic 
that we will be successful for two rea-
sons. One, I think there are great people 
involved who have a lot of bright ideas. 
And second, I see more and more evi-
dence of resistance to infection after 
exposure, which means that we need to 
work out why it’s possible to be exposed 
and not infected.
I think the trouble with the HIV 
vaccine is that expectations were incred-
ibly high, both in the community and 
among scientists. We have to realize that 
this is an iterative process. I don’t think 
it will come in five years, but I do think 
it will come.
How did you feel when you heard that 
Merck’s HIV vaccine trial was canceled?
I remember saying, “Oh, [expletive]!” 
I remember being upset when I heard 
some people saying that they could 
have predicted it, because I don’t think 
one could have predicted that there 
would be an adverse eff  ect. I think the 
outcome will be okay but it was a very 
troubling time, and it’s still troubling 
because I think it really illustrated to us 
how diffi   cult a vaccine will be.
I also worry that it gave T cell vac-
cines a bad name. But it’s turning out 
that there were confounding factors, 
that it wasn’t just the adenovirus vec-
tor that was the problem. For exam-
ple, the circumcision data for these 
individuals seemed to play a big role. 
Still, I think it’s good that everyone 
stopped to take a breather, because 
even if the effects of the vaccine were 
just futile, I think we should have 
stopped to reassess what we needed to 
make a vaccine.
FRONT LINES OF DEFENSE
Why do you devote so much attention to 
the gut?
About fi  ve years ago we looked at the 
gastrointestinal tract of HIV-infected 
individuals  and we found that within 
the fi  rst two to three weeks of infection, 
the majority of all the CD4  +   T cells in 
the gastrointestinal tract are depleted. 
The reason why that’s important is that 
the gastrointestinal tract contains the 
majority of all the T cells in the body, 
so our theory is that you lose the major-
ity of your CD4  +   T cells in the acute 
phase of the infection.
Recently, we and others found that 
among the disappearing CD4  +   T cells, 
Th17 cells are preferentially depleted, 
which is interesting because Th17 cells 
are thought to be important in the 
control of microbes at mucosal surfaces. 
In fact, we published a paper on a rare 
disease called Job’s syndrome in which 
people have terrible bacterial and fungal 
infections. We found that they’re unable 
to elicit Th17 cells (5). In terms of HIV, 
we want to understand the effect of a 
preferential loss of Th17 cells because 
that then becomes an avenue for thera-
peutic intervention.
What do you think of the “elite controllers” 
who somehow keep viral loads low?
I think they’re an absolutely fascinat-
ing group of people, and if we can 
learn from them, we can learn about 
pathogenesis, therapies, and vaccines. 
Right now we are working with a 
group of elite controllers to dissect 
their T cell receptors and study their 
T cell responses.
I think these extremes are also go-
ing to tell us a lot with respect to host 
genetic factors that might be responsible 
for either a poor prognosis or for non-
progression. For example, we know that 
most viruses use the CCR5 coreceptor 
to infect a CD4  +   T cell. Individuals 
who have a homozygous deletion in 
part of CCR5, so that it’s not expressed 
on the cell surface, can’t be infected by 
HIV that uses CCR5. This means that 
one could design a drug to block 
CCR5. And in fact, those drugs exist 
and are being administered to humans 
at the moment.
Does the fact that individuals like these 
exist indicate that we may be evolving 
to resist the virus?
That’s a great question. Natural hosts 
for SIV, such as African green monkeys 
and sooty mangabeys, do not get AIDS 
although they have high viral loads. 
And so there are clearly host factors 
responsible  for that nonprogressive 
state. I think it’s critical for us to go to 
Africa and investigate these natural 
hosts to understand what 
makes their disease non-
progressive and to see if 
there are any therapeutic 
avenues open to us.
Obviously, if a million 
years ago there was a pan-
demic in African green 
monkeys and the only 
ones who could live with 
the virus are the ones who 
survived,  that’s interesting from the 
point of evolution. But we as humans 
are not afforded that experiment; we 
have to do something now.
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HIV-infected intestines lose CD4  +   T cells (brown) early on.
“We need to 
work out why 
it’s possible 
to be exposed 
[to HIV] and 
not infected.”